Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

A panelist discusses how the COCOON study demonstrated that enhanced dermatologic management significantly reduces the ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal ...

Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment ...

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

The study advanced beyond a one-size-fits-all model by developing both a global XGBoost classifier and cancer-type-specific ...

Elara had already factored in approximately $20 million in revenue from gAbraxane in the US for FY26. While 3–4 generic ...